WALTHAM,
Mass., Nov. 21, 2022 /PRNewswire/ -- Syndax
Pharmaceuticals, Inc. (Nasdaq: SNDX), a clinical-stage
biopharmaceutical company developing an innovative pipeline of
cancer therapies, today announced that members of its management
team will participate in a fireside chat at the Evercore ISI Annual
HealthCONx Conference on Wednesday, November
30, 2022, at 3:30 p.m. ET.
A live webcast of the fireside chat can be accessed from the
Investor section of the Company's website at www.syndax.com, where
a replay of the event will also be available for a limited
time.
About Syndax Pharmaceuticals,
Inc.
Syndax Pharmaceuticals is a clinical stage biopharmaceutical
company developing an innovative pipeline of cancer therapies.
Highlights of the Company's pipeline include revumenib (SNDX-5613),
a highly selective inhibitor of the Menin–MLL binding interaction,
and axatilimab, a monoclonal antibody that blocks the colony
stimulating factor 1 (CSF-1) receptor, both currently in pivotal
trials. For more information, please visit www.syndax.com or follow
the Company on Twitter and LinkedIn.
Syndax Contacts
Sharon Klahre
Syndax Pharmaceuticals, Inc.
sklahre@syndax.com
Tel 781.684.9827
SNDX-G
View original
content:https://www.prnewswire.com/news-releases/syndax-announces-participation-at-evercore-isi-annual-healthconx-conference-301683415.html
SOURCE Syndax Pharmaceuticals, Inc.